

Edgar Filing: EPIX Pharmaceuticals, Inc. - Form SC 13G

EPIX Pharmaceuticals, Inc.
Form SC 13G
March 03, 2005

SECURITIES & EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G
Under the Securities and Exchange Act of 1934

(Amendment No. ____)*

EPIX Pharmaceuticals, Inc.
(Name of Issuer)

Common Stock
(Title of Class of Securities)

26881Q101
(CUSIP Number)

February 25, 2005
(Date of event which requires filing of this statement)

Check the appropriate box to designate the rule pursuant to which this
Schedule 13G is filed:

- ☐ Rule 13d-1(b)
☒ Rule 13d-1(c)
☐ Rule 13d-1(d)

(Page 1 of 12 Pages)

*The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would
alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be
deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act
of 1934 ("Act") or otherwise subject to the liabilities of that section of the
Act but shall be subject to all other provisions of the Act (however, see the
Notes).

CUSIP No.26881Q101

13G

Page 2 of 12 Pages

- (1) NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO.
OF ABOVE PERSONS (ENTITIES ONLY)

Hunter Global Associates L.L.C.

Edgar Filing: EPIX Pharmaceuticals, Inc. - Form SC 13G

(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP **		(a) ☒	(b) ☐
(3) SEC USE ONLY			
(4) CITIZENSHIP OR PLACE OF ORGANIZATION			
Delaware			
NUMBER OF	(5) SOLE VOTING POWER	-0-	
SHARES			
BENEFICIALLY	(6) SHARED VOTING POWER	331,950	
OWNED BY			
EACH	(7) SOLE DISPOSITIVE POWER	-0-	
REPORTING			
PERSON WITH	(8) SHARED DISPOSITIVE POWER	331,950	
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		331,950	
(10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES **		☐	
(11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)		1.4%	
(12) TYPE OF REPORTING PERSON **		OO	

** SEE INSTRUCTIONS BEFORE FILLING OUT!

CUSIP No.26881Q101

13G

Page 3 of 12 Pages

(1) NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)			
Hunter Global Investors L.P.			
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP **		(a) ☒	(b) ☐
(3) SEC USE ONLY			

Edgar Filing: EPIX Pharmaceuticals, Inc. - Form SC 13G

(4) CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware

NUMBER OF (5) SOLE VOTING POWER
SHARES -----
BENEFICIALLY (6) SHARED VOTING POWER
OWNED BY -----
EACH (7) SOLE DISPOSITIVE POWER
REPORTING -----
PERSON WITH (8) SHARED DISPOSITIVE POWER

-0-

1,202,685

-0-

1,202,685

(9) AGGREGATE AMOUNT BENEFICIALLY OWNED
BY EACH REPORTING PERSON

1,202,685

(10) CHECK BOX IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES **

[]

(11) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9)

5.2%

(12) TYPE OF REPORTING PERSON **

IA

** SEE INSTRUCTIONS BEFORE FILLING OUT!

CUSIP No.26881Q101

13G

Page 4 of 12 Pages

(1) NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO.
OF ABOVE PERSONS (ENTITIES ONLY)

Duke Buchan III

(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP **

(a) [X]

(b) []

(3) SEC USE ONLY

(4) CITIZENSHIP OR PLACE OF ORGANIZATION
United States

NUMBER OF (5) SOLE VOTING POWER
SHARES -----
BENEFICIALLY (6) SHARED VOTING POWER

-0-

Edgar Filing: EPIX Pharmaceuticals, Inc. - Form SC 13G

OWNED BY	-----	1,202,685	-----
EACH	(7) SOLE DISPOSITIVE POWER	-0-	
REPORTING	-----		
PERSON WITH	(8) SHARED DISPOSITIVE POWER	1,202,685	
(9)	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	1,202,685	
(10)	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES **	[]	
(11)	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)	5.2%	
(12)	TYPE OF REPORTING PERSON **	IN	

*** SEE INSTRUCTIONS BEFORE FILLING OUT!

CUSIP No.26881Q101 13G Page 5 of 12 Pages

(1)	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)	
	Hunter Global Investors Fund I L.P.	
(2)	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP **	(a) [X] (b) []
(3)	SEC USE ONLY	
(4)	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware	
NUMBER OF	(5) SOLE VOTING POWER	-0-
SHARES	-----	
BENEFICIALLY	(6) SHARED VOTING POWER	318,720
OWNED BY	-----	
EACH	(7) SOLE DISPOSITIVE POWER	-0-
REPORTING	-----	

Edgar Filing: EPIX Pharmaceuticals, Inc. - Form SC 13G

PERSON WITH	(8)	SHARED DISPOSITIVE POWER	318,720

(9)	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		318,720

(10)	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES **		[]

(11)	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)		1.4%

(12)	TYPE OF REPORTING PERSON **		PN

** SEE INSTRUCTIONS BEFORE FILLING OUT!

CUSIP No.26881Q101 13G Page 6 of 12 Pages

(1)	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)		
Hunter Global Investors Fund II L.P.			

(2)	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP **		(a) [X] (b) []

(3)	SEC USE ONLY		

(4)	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware		

NUMBER OF	(5)	SOLE VOTING POWER	-0-
SHARES	-----		
BENEFICIALLY	(6)	SHARED VOTING POWER	13,230
OWNED BY	-----		
EACH	(7)	SOLE DISPOSITIVE POWER	-0-
REPORTING	-----		
PERSON WITH	(8)	SHARED DISPOSITIVE POWER	13,230

(9)	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		13,230

(10)	CHECK BOX IF THE AGGREGATE AMOUNT		

Edgar Filing: EPIX Pharmaceuticals, Inc. - Form SC 13G

IN ROW (9) EXCLUDES CERTAIN SHARES **

[]

(11) PERCENT OF CLASS REPRESENTED
BY AMOUNT IN ROW (9)

0.1%

(12) TYPE OF REPORTING PERSON **

PN

** SEE INSTRUCTIONS BEFORE FILLING OUT!

CUSIP No.26881Q101

13G

Page 7 of 12 Pages

Item 1(a). Name of Issuer:

The name of the issuer is EPIX Pharmaceuticals, Inc.
(the "Issuer").

Item 1(b). Address of Issuer's Principal Executive Offices:

The Issuer's principal executive offices are located at
161 First Street, Cambridge, MA 02142

Item 2(a). Name of Person Filing:

This statement is filed by:

- (i) Hunter Global Associates L.L.C., a Delaware limited liability company ("Associates") (OO) that is the general partner of Hunter Global Investors Fund I L.P. ("Fund I") and Hunter Global Investors Fund II L.P. ("Fund II"), with respect to the shares of Common Stock (defined in Item 2(d) below) beneficially owned by Fund I and Fund II, collectively.
- (ii) Hunter Global Investors L.P., a Delaware limited partnership ("Investors") (IA) that is the investment manager of Fund I, Fund II, Hunter Global Investors Offshore Fund Ltd., a Cayman Islands exempted company ("Off I") and Hunter Global Investors Offshore Fund II Ltd., a Cayman Islands exempted company ("Off II"), with respect to the shares of Common Stock beneficially owned by Fund I, Fund II, Off I and Off II, collectively.
- (iii) Duke Buchan III ("Mr. Buchan") (IN), who is the managing member of Associates and who controls Investors through its general partner, with respect to the shares of Common Stock beneficially owned by Fund I, Fund II, Off I and Off II, collectively.
- (iv) Fund I, a Delaware limited partnership (PN), with respect to the shares of Common Stock beneficially owned by it.
- (v) Fund II, a Delaware limited partnership (PN), with respect to the shares of Common Stock beneficially owned by it.

Edgar Filing: EPIX Pharmaceuticals, Inc. - Form SC 13G

The foregoing persons are hereinafter collectively referred to as the "Reporting Persons". Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate person.

Item 2(b). Address of Principal Business Office or, if none, Residence

The address of the business office of each of the Reporting Persons is 485 Madison Avenue, 22nd Floor, New York, New York 10022.

CUSIP No.26881Q101

13G

Page 8 of 12 Pages

Item 2(c). Citizenship

Fund I, Fund II and Investors are each limited partnerships organized under the laws of the State of Delaware. Associates is a limited liability company organized under the laws of the State of Delaware. Mr. Buchan is a United States citizen.

Item 2(d). Title of Class of Securities

Common Stock (the "Common Stock")

Item 2(e). CUSIP Number

26881Q101

Item 3. If this statement is filed pursuant to Rules 13d-1(b) or 13d-2(b) or (c), check whether the person filing is a: NOT APPLICABLE

- (a) ☐ Broker or dealer registered under Section 15 of the Act,
- (b) ☐ Bank as defined in Section 3(a)(6) of the Act,
- (c) ☐ Insurance Company as defined in Section 3(a)(19) of the Act,
- (d) ☐ Investment Company registered under Section 8 of the Investment Company Act of 1940,
- (e) ☐ Investment Adviser in accordance with Rule 13d-1(b)(1)(ii)(E),
- (f) ☐ Employee Benefit Plan or Endowment Fund in accordance with 13d-1(b)(1)(ii)(F), (g) ☐ Parent Holding Company or control person in accordance with Rule 13d-1(b)(1)(ii)(G),
- (h) ☐ Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act,
- (i) ☐ Church Plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940,
- (j) ☐ Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

Item 4. Ownership.

The percentages used in this Item 4 are calculated based upon 23,089,499 shares of Common Stock issued and outstanding as reported on Form 10-Q filed by the Issuer with the Commission on November 2, 2004.

- A. Hunter Global Associates L.L.C., as general partner of Hunter Global Investors Fund I L.P. and Hunter Global Investors Fund II L.P.

Edgar Filing: EPIX Pharmaceuticals, Inc. - Form SC 13G

- (a) Amount beneficially owned: 331,950
- (b) Percent of class: 1.4%

CUSIP No.26881Q101

13G

Page 9 of 12 Pages

- (c) (i) Sole power to vote or direct the vote: -0-
 - (ii) Shared power to vote or direct the vote: 331,950
 - (iii) Sole power to dispose or direct the disposition: -0-
 - (iv) Shared power to dispose or direct the disposition: 331,950
- B. Hunter Global Investors L.P., as investment manager of Hunter Global Investors Fund I L.P., Hunter Global Investors Fund II L.P., Hunter Global Investors Offshore Fund Ltd. and Hunter Global Investors Offshore Fund II Ltd.
 - (a) Amount beneficially owned: 1,202,685
 - (b) Percent of class: 5.2%
 - (c) (i) Sole power to vote or direct the vote: -0-
 - (ii) Shared power to vote or direct the vote: 1,202,685
 - (iii) Sole power to dispose or direct the disposition: -0-
 - (iv) Shared power to dispose or direct the disposition: 1,202,685
- C. Duke Buchan III, as senior managing member of Hunter Global Associates L.L.C., and as the sole member of the general partner of Hunter Global Investors L.P.
 - (a) Amount beneficially owned: 1,202,685
 - (b) Percent of class: 5.2%
 - (c) (i) Sole power to vote or direct the vote: -0-
 - (ii) Shared power to vote or direct the vote: 1,202,685
 - (iii) Sole power to dispose or direct the disposition: -0-
 - (iv) Shared power to dispose or direct the disposition: 1,202,685
- D. Hunter Global Investors Fund I L.P.
 - (a) Amount beneficially owned: 318,720
 - (b) Percent of class: 1.4%
 - (c) (i) Sole power to vote or direct the vote: -0-
 - (ii) Shared power to vote or direct the vote: 318,720
 - (iii) Sole power to dispose or direct the disposition: -0-
 - (iv) Shared power to dispose or direct the disposition: 318,720
- E. Hunter Global Investors Fund II L.P.
 - (a) Amount beneficially owned: 13,230
 - (b) Percent of class: 0.1%
 - (c) (i) Sole power to vote or direct the vote: -0-
 - (ii) Shared power to vote or direct the vote: 13,230
 - (iii) Sole power to dispose or direct the disposition: -0-
 - (iv) Shared power to dispose or direct the disposition: 13,230

Edgar Filing: EPIX Pharmaceuticals, Inc. - Form SC 13G

CUSIP No.26881Q101

13G

Page 10 of 12 Pages

Item 5. Ownership of Five Percent or Less of a Class

Not applicable.

Item 6. Ownership of More than Five Percent on Behalf of Another Person

Mr. Buchan, the senior managing member of Associates and the sole member of the general partner of Investors, has the power to direct the affairs of Associates, Investors, Fund I, Fund II, Off I and Off II, including decisions with respect to the disposition of proceeds from the sale of the Common Stock.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

Not applicable.

Item 8. Identification and Classification of Members of the Group

The identity of each member of the group is set forth above under Item 2(a) and Item 4.

Item 9. Notice of Dissolution of Group

Not applicable.

CUSIP No.26881Q101

13G

Page 11 of 12 Pages

Item 10. Certification.

Each of the Reporting Persons hereby makes the following certification:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURES

After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

DATED: March 3, 2005

By: /s/ DUKE BUCHAN III

Duke Buchan III, individually and (a) as Senior Managing Member of Hunter Global Associates L.L.C., for itself and as the general partner of (i) Hunter Global Investors Fund I L.P. and (ii) Hunter Global Investors Fund II L.P. and (b) as Managing Member of Hunter Global Capital Management L.L.C., as the general partner of Hunter Global Investors L.P.

Edgar Filing: EPIX Pharmaceuticals, Inc. - Form SC 13G

CUSIP No.26881Q101

13G

Page 12 of 12 Pages

EXHIBIT 1

JOINT ACQUISITION STATEMENT
PURSUANT TO RULE 13d-1(k)

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

DATED: March 3, 2005

By: /s/ DUKE BUCHAN III

Duke Buchan III, individually and (a) as Senior Managing Member of Hunter Global Associates L.L.C., for itself and as the general partner of (i) Hunter Global Investors Fund I L.P. and (ii) Hunter Global Investors Fund II L.P. and (b) as Managing Member of Hunter Global Capital Management L.L.C., as the general partner of Hunter Global Investors L.P.